Ocular’s OTX-DED Succeeds In Dry Eye Where OTX-CSI Failed, But More Data Needed
Executive Summary
The Phase II trial showed significant improvement in eye redness in patients with dry eye disease, but additional data are needed on DED symptom improvement.
You may also be interested in...
Aldeyra Therapeutics Eyes First Line Market As Phase II Dry Eye Candidate Impresses
The firm’s lead asset, reproxalap, one-upped Novartis’s Xiidra in a mid-stage ophthalmology study, signalling its first-line promise in a market ridden with compliance issues.
Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.
Ocular’s Dry Eye Drug Fails In Phase II, But It Isn’t Giving Up Yet
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.